An Exploratory, Prospective, Multi-Center, Open-Label, Single-Arm, Interventional, Phase IIB Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Patients With Diabetic Macular Edema Treated With Faricimab (RO6867461) - ALTIMETER STUDY
Latest Information Update: 04 Dec 2023
At a glance
- Drugs Faricimab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms ALTIMETER
- Sponsors Roche
Most Recent Events
- 11 Jan 2023 Last checked against European Clinical Trials Database record.
- 23 Dec 2022 Status changed from active, no longer recruiting to completed.
- 22 Nov 2022 Planned End Date changed from 28 Dec 2022 to 12 Dec 2022.